Forton FMN, et al. - Researchers conducted this retrospective observational study to assess the effect of topical benzyl benzoate [BB] (+crotamiton) treatment on Demodex densities (Dds) and clinical symptoms of rosacea and demodicosis and compared three BB treatment regimens. The study sample consisted of 394 patients (117 with rosacea, 277 with demodicosis). Three BB (+crotamiton) treatment regimens were compared for this investigation: 12% once daily, 12% twice daily and 20% once daily. The authors discovered that the total Dd (SSSB1+2) had decreased by 72.4 ± 2.6% from the initial value across the whole cohort at an average of 2.7 months after treatment start. Data reported that treatment was effective in 183 patients and curative in 78 patients. Compared with other doses, the 12% once daily regimen was less efficient and had poorer compliance than the 12% twice daily regimen. Overall, the investigators concluded that topical BB (+crotamiton) treatment can be an effective treatment for rosacea as well as demodicosis, indirectly supporting a key role of the mite in rosacea pathophysiology. The two dose regimens that were higher than the lower dose were more effective.